Background Some patients with plaque psoriasis experience secondary failure of tumour necrosis factor inhibitor therapy. Objectives To evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. Methods This phase IV open-label single-arm estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static Physician's Global Assessment (sPGA) score 0/1 (clear/almost clear). Patients subsequently lost response, defined as sPGA ≥ 3 or loss of 50% improvement in Psoriasis Area and Severity Index (PASI 50). At baseline, patients had involved body surface area ≥ 10%, sPGA ≥ 3 and PASI ≥ 10. Antiadalimumab antibodies (ADAs) were measured at screening. Patients received etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly. The primary end point was sPGA 0/1 at week 12 (intention-to-treat analysis; no hypothesis tested). Additional outcomes included rates of sPGA 0/1, PASI responses, safety, PROs of itch, pain and flaking, Dermatology Life Quality Index, treatment satisfaction and Work Productivity and Activity Impairment questionnaire. Results Sixty-four patients enrolled; 67% had ADAs. sPGA 0/1 rates at week 12 were 39Á7% [95% confidence interval (CI) 27Á6-52Á8; primary end point] and 45% (95% CI 29Á3-61Á5) for patients positive for ADAs and 35% (95% CI 15Á4-59Á2) for patients negative for ADAs. PASI 75 response rates at week 12 were 47Á5% (95% CI 31Á5-63Á9) for patients who were positive for ADAs and 50% (95% CI 27Á2-72Á8) for patients negative for ADAs. No new safety signals were observed. PROs of itch, pain and flaking consistently improved at week 12 and were maintained through week 24. Conclusions Patients with psoriasis who experienced secondary failure of adalimumab achieved satisfactory response to etanercept regardless of ADA status.
• Response to etanercept was not affected by the presence of antiadalimumab antibodies.
Psoriasis is a chronic systemic inflammatory autoimmune disease that manifests in the skin. Susceptibility to psoriasis in some patients has been linked to the HLA-Cw6 allele, located in the major histocompatibility complex locus. 1 The prevalence and incidence of psoriasis varies by geographical region. 2 A recent meta-analysis of global psoriasis epidemiology reported an estimated prevalence of 0Á73-2Á9% in Europe and the U.S.A. 2 The incidence of psoriasis was 120-140 cases per 100 000 person-years in Europe and 60 cases per 100 000 person-years in the U.S.A. 2 Notably, psoriasis is associated with a higher prevalence of cardiovascular disease, obesity, diabetes, hypertension, dyslipidaemia, metabolic syndrome, nonalcoholic fatty liver disease and cancer compared with the general population. 3 Patients with psoriasis commonly report symptoms of itch, pain, burning, stinging, cracking, scaling, flaking and redness. 4 Disability-adjusted life years lost have been estimated to be 22-25 years and 12-14 years per 100 000 in Western Europe and the U.S.A., respectively. This represents a significant burden of disease. 5 Currently approved therapies for psoriasis include topical agents (e.g. corticosteroids, vitamin D3), phototherapy and systemic therapies including nonbiological agents (e.g. methotrexate, ciclosporin, apremilast) and biologics (e.g. adalimumab, etanercept, infliximab, ustekinumab, secukinumab). Adalimumab and etanercept are tumour necrosis factor (TNF)-inhibitor (TNFi) medications that are commonly used for the treatment of moderate-to-severe plaque psoriasis. Adalimumab is a fully human monoclonal antibody that binds to TNF and blocks its interaction with the p55 and p75 cell surface TNF receptors. 6 Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to TNF and block its interaction with TNF receptors at the cell surface. 7 Many patients are managed satisfactorily on adalimumab or etanercept, but some experience loss of effect over time. Recent studies have shown that patients with psoriasis who have failed to achieve an initial response or lost response to etanercept can benefit from adalimumab treatment. [8] [9] [10] Loss of response to adalimumab may be due to antiadalimumab antibodies in some patients. These antibodies developed frequently in patients with psoriasis (up to 49% of patients), [11] [12] [13] [14] [15] but did not cross-react with etanercept. 12 The diminished clinical response to adalimumab correlated with the development of antiadalimumab antibodies and low serum trough adalimumab levels. This loss of efficacy may occur by the formation of immune complexes promoting rapid drug clearance, as has been shown for infliximab, 16 or by neutralizing the binding activity of the antibody to TNF. Evidence for a clinical benefit of etanercept treatment in patients with plaque psoriasis who have lost response to adalimumab is limited. As some patients with antiadalimumab antibodies are otherwise responsive to TNF inhibition, it is hypothesized that subsequent treatment with another TNFi would lead to a greater response in those with antiadalimumab antibodies compared with those without the antibodies. The objectives of this study were to evaluate efficacy, safety and patient-reported outcomes (PROs) with etanercept in adults with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
Patients and methods

Study design
This was a phase IV open-label single-arm estimation study.
The study comprised a 45-day screening period and a 24-week treatment period, with study visits every 4 weeks. Etanercept dosing followed the recommended label dosing for patients with psoriasis, i.e. 50 mg twice weekly administered subcutaneously for 12 weeks followed by 50 mg once weekly for an additional 12 weeks. Patients were followed up for~30 days after the last dose of etanercept. This study was conducted in accordance with the Declaration of Helsinki, and was approved by the Institutional Review Board at each study site. All patients provided written, informed consent before initiation of study-related procedures. This study was registered under the ClinicalTrials.gov identifier NCT01543204.
Patients
Eligible patients were aged ≥ 18 years and were currently receiving treatment with adalimumab for plaque psoriasis, or had discontinued adalimumab treatment within 6 months prior to screening. Patients who were currently receiving adalimumab completed a 2-week washout period prior to receiving the first dose of etanercept. Patients were required to have originally had a satisfactory response to adalimumab, as defined by a static Physician's Global Assessment (sPGA) of clear/almost clear (score 0/1). In the absence of an sPGA measurement, a 75% improvement in Psoriasis Area and Severity Index (PASI 75 response) or 75% improvement in psoriasis-affected body surface area (BSA) in response to adalimumab was acceptable if the investigator felt that the patient had also achieved the equivalent of a clear or almost clear response. Patients subsequently had to have a documented loss of satisfactory response to adalimumab as defined by an sPGA score ≥ 3 (moderate or worse) or loss of PASI 50 response or equivalent in the opinion of the investigator, and to have been compliant with a stable dosage (no dosage reductions) of adalimumab. At baseline, patients were required to have sPGA ≥ 3, PASI score ≥ 10 and involved BSA ≥ 10%.
Antiadalimumab antibody testing
Antiadalimumab antibodies were measured at screening. A two-tiered approach was used to test for antiadalimumab antibodies, which included a screening and a specificity assay. Samples were first treated with low pH buffer to dissociate antibody-drug complexes, and then tested in a validated electrochemiluminescence (ECL)-based bridging immunoassay. Screened samples with a signal-to-noise ratio greater than the assay cut point were confirmed in the specificity assay; samples in the specificity assay that showed a signal-to-noise ratio reduction in the presence of excess soluble adalimumab were reported as positive. An affinity-purified rabbit antiadalimumab antibody was used as a positive control antibody in the assays.
The detection of neutralizing antibodies was based on a competitive binding assay that used soluble TNF-biotin, which forms a complex with ruthenylated drug. The complex was captured on a Streptavidin Gold MSD plate (Meso Scale Diagnostics LLC, Rockville, MD, U.S.A.). Antiadalimumab-neutralizing antibodies compete with TNF-biotin for binding to ruthenylated drug, resulting in a reduction of ECL signal. The presence of neutralizing antibodies was detected using an excess amount of adalimumab. The assay sensitivity was 0Á86 lg mL À1 .
End points
Efficacy end points included an sPGA of clear/almost clear (score 0/1) at week 12 (primary end point) and throughout the study, and PASI 50, PASI 75 and PASI 90 responses and psoriasis-affected BSA throughout the study. Efficacy end points were analysed based on an intention-to-treat sample and were also stratified by antiadalimumab antibody status (yes/no). Safety end points included the incidence of adverse events (AEs) and serious AEs (SAEs) throughout the study. PROs included patient assessments of pain, itch and flaking, changes in Dermatology Life Quality Index (DLQI), 17 patient satisfaction with treatment, and Work Productivity and Activity Impairment (WPAI) questionnaire 18 at weeks 12 and 24. Patient assessments of pain, itch and flaking were based on a visual analogue scale of 0 (none) to 10 (worst). The work productivity items on the WPAI were administered to employed patients only.
Statistical considerations
This study was designed to provide an estimate of the proportion of patients who would achieve an sPGA of clear/almost clear after 12 weeks of etanercept treatment following a loss of satisfactory response to adalimumab. A sample size of approximately 100 patients was estimated to provide an adequate half-width of the 95% confidence interval (CI) based on results from placebo-controlled studies that showed a 35-49% rate of sPGA of clear/almost clear with etanercept and~5% for placebo. 19, 20 Approximately 40% of patients were estimated to have antiadalimumab antibodies, 12, 21 and the rate of sPGA response was expected to be higher in patients who were positive for antibodies than for those without antiadalimumab antibodies. The primary end point was the proportion of patients with an sPGA status of clear/almost clear (score 0/1) at week 12. As this was an estimation study, no formal hypothesis was tested. For efficacy end points, 95% CIs and P-values were generated to describe the difference in response between positive and negative antiadalimumab antibody subgroups. No multiplicity adjustments were made for P-values. The primary analysis for efficacy end points used last observation carried forward imputation for missing data. Efficacy measures were also estimated for antiadalimumab antibody-positive and antibody-negative subgroups separately. Analyses based on antiadalimumab antibody subgroups and PRO assessments were analysed as observed, with no imputation for missing data. All analyses were performed on the full analysis set, which comprised all patients who received at least one dose of etanercept. AEs were summarized and coded using the Medical Dictionary for Regulatory Activities version 18Á0. Statistical analyses were performed using SAS version 9Á2 (SAS Institute Inc., Cary, NC, U.S.A).
Results
Patients
Only 64 of 100 planned patients were enrolled; the study was closed early because of recruitment issues. Patients were enrolled between 1 February 2012 (first patient enrolled) and 29 May 2015 (last patient visit) from 48 sites in the U.S.A. Of 64 enrolled patients, 56 completed the study and eight discontinued because of withdrawn consent (n = 4), noncompliance (n = 1), AE (n = 1), requirement for alternative therapy (n = 1) or were lost to follow-up (n = 1). Most patients were male (63%) and of white ethnicity (83%) ( Table 1 ). A total of 43 patients (67%) tested positive for antiadalimumab antibodies, of which 26 patients (41%) had neutralizing antibodies, and 21 patients (33%) were negative for antibodies.
Efficacy outcomes
Across all patients, the rate of sPGA response of clear/almost clear at week 12 was 39Á7% (95% CI 27Á6-52Á8) (Fig. 1a) . At week 12, 45% of patients (95% CI 29Á3-61Á5) with antiadalimumab antibodies and 35% of patients (95% CI 15Á4-59Á2) without antiadalimumab antibodies had achieved an sPGA of clear/almost clear (Fig. 1b) . The difference in sPGA response rates between the two groups was not statistically significant at any time during the study. Fig. 2) and percentage improvements in psoriasisaffected BSA (Fig. 3) were generally similar between patients with and without antiadalimumab antibodies. Overall, efficacy outcomes were maintained through week 24 of the study. AEs, adverse events. Data are provided as n (%). 
Safety
A total of 40 patients (63%) reported a treatment-emergent AE (Table 2) . Of these, AEs reported by 16 patients (25%) were considered by the investigator to be related to etanercept. One patient discontinued the study because of a cough. Vitamin D deficiency was reported by five patients (8%); vitamin D levels were assessed at baseline only. Two SAEs were reported by two patients; ischaemic colitis (n = 1; considered by the investigator to be related to treatment) and diverticulitis (n = 1; considered by the investigator to be not related to treatment). No patient died during the study. No new safety signals were observed.
Patient-reported outcomes
Improvements in patient assessments of itch, pain and flaking were observed at week 12, and were maintained through week 24 (Fig. 4) . The mean (SD) DLQI total score improved from 12Á7 (6Á7) at baseline to 4Á8 (5Á0) at week 12 and 5Á2 (6Á3) at week 24. Only 6% of patients were satisfied or very satisfied with treatment at baseline (Fig. 5) . Overall, 63% and 57% of patients were satisfied or very satisfied with treatment at weeks 12 and 24, respectively. For patients who were employed, absenteeism (missing work because of psoriasis) was low at baseline and throughout the study (Fig. 6) . Rates of presenteeism (attending work while ill as a result of psoriasis) and loss of productivity at work because of psoriasis improved from baseline at weeks 12 and 24. Impairment in daily activity was relatively high across all patients at baseline (mean 36% impairment) and improved at weeks 12 and 24.
Discussion
TNFi medications are often employed as a second-line biological agent after failure of, or loss of response to, an initial TNFi. Response to etanercept as a second TNFi has been evaluated in patients with rheumatoid arthritis with and without antiadalimumab or anti-infliximab antibodies compared with patients who were naive for anti-TNFi. 21 That study demonstrated a correlation between an immunogenic response to a prior TNFi medication and the level of etanercept efficacy. Patients with rheumatoid arthritis without antidrug antibodies had a diminished clinical response to etanercept compared with patients with antidrug antibodies, whereas patients with antidrug antibodies had a similar response to patients who were naive for TNFi. 21 We sought to assess whether a similar relationship exists in patients with psoriasis who experienced secondary failure of adalimumab. In the small population of patients with plaque psoriasis evaluated in our study, there were no consistent differences in response to etanercept between patients who were positive for antiadalimumab antibodies and those who were negative for antiadalimumab antibodies.
In our study, patients with psoriasis with antiadalimumab antibodies had numerically better rates of sPGA of clear/almost clear compared with patients without antibodies at most time points, but the differences were not statistically significant. Overall, rates of sPGA of clear/almost clear in our study, representing patients who experienced secondary failure of adalimumab (40% at week 12 and 38% at week 24), were lower than rates seen in patients who were naive for biologics on the same dosing regimen (range 46-49% at week 12; 19, 22, 23 56% at week 24), 23 and patients with primary adalimumab failure (50% at week 12 and 70% at week 24). 24 Surprisingly, rates of PASI 50 responses throughout the study and PASI 75 responses through week 12 were numerically highest in patients without antibodies, whereas rates of PASI 90 responses were highest in patients with antibodies (although none of the differences was statistically significant).
Rates of PASI responses at week 12 in our study were similar to those in patients who were naive for biologics. 19, 20, 23 The importance of outcomes from the patient's perspective is increasingly recognized. In this study, patients reported improvements in the severity of symptoms (itch, pain and flaking) and in satisfaction with treatment. Additionally, changes in DLQI score from baseline to weeks 12 and 24 were greater than the minimum clinically important difference. 25 Employed patients reported improvements in both presenteeism and loss of productivity at work, although rates of absenteeism were low throughout the study. Employed and unemployed patients also reported less impairment in activity.
This study had some limitations. The open-label nature of the study limits the interpretation of the findings, although the investigators were blinded to the antiadalimumab status of the patients. The size of the patient population was small, and further limited by the early termination of enrolment because of difficulties in recruitment. The limited number of patients in the study poses difficulties in making meaningful comparisons of outcome measures between groups. Future studies that address the issue of response to subsequent treatment in patients with antidrug antibodies should obtain a larger sample size than was achieved in our study.
In this study of patients with psoriasis who had experienced a secondary failure of adalimumab therapy, treatment with etanercept resulted in improvements in rates of sPGA of clear/almost clear and PASI responses. The presence of antiadalimumab antibodies did not appear to affect response to etanercept, although this finding is limited by the small sample size of the study. The results of PRO measures demonstrated a consistent and favourable impact across several end points. No new safety concerns were observed. Clinicians may consider treatment with etanercept following secondary failure of adalimumab in patients with moderate-to-severe plaque psoriasis.
